Showing 1 posts of 1 posts found.
Russia’s largest drug company Pharmstandard has agreed a $590 million deal to buy the Singapore-based supplier of active pharmaceutical ingredients …
Qureight paper argues for fibrosis extent as imaging biomarker in lung disease trials
START and Rome cancer institute partner to expand early-phase trial access in Italy
AbbVie expands Oxford R&D facility with new £120m UK research commitment
MedPharm appoints Jason Mieding as chief operating officer
UKRI backs five hubs developing AI tools for earlier disease detection